Characterization of a key neutralizing epitope on pertussis toxin recognized by monoclonal antibody 1B7.

Despite more than five decades of research and vaccination, infection by Bordetella pertussis remains a serious disease with no specific treatments or validated correlates of protective immunity. Of the numerous monoclonal antibodies binding pertussis toxin (PTx) that have been produced and characterized, murine IgG2a monoclonal antibody 1B7 is uniquely neutralizing in all in vitro assays and in vivo murine models of infection. 1B7 binds an epitope on the enzymatically active S1 subunit of PTx (PTx-S1) with some linear elements, but previous work with S1 scanning peptides, phage-displayed peptide libraries, and S1 truncation/deletion variants was unable to more precisely define the epitope. Using computational docking algorithms, alanine scanning mutagenesis, and surface plasmon resonance, we characterize the epitope bound by 1B7 on PTx-S1 in molecular detail and define energetically important interactions between residues at the interface. Six residues on PTx-S1 and six residues on 1B7 were identified that, when altered to alanine, resulted in variants with significantly reduced affinity for the native partner. Using this information, a model of the 1B7-S1 interaction was developed, indicating a predominantly conformational epitope located on the base of S1 near S4. The location of this epitope is consistent with previous data and is shown to be conserved across several naturally occurring strain variants, including PTx-S1A, -B (Tohama-I), -D, and -E (18-323) in addition to the catalytically inactive 9K/129G variant. This highly neutralizing but poorly immunogenic epitope may represent an important target for next-generation vaccine development, identification of immune correlates, and passive immunization strategies for pertussis.

[1]  J. Mertsola,et al.  Rapid Typing of Bordetella pertussis Pertussis Toxin Gene Variants by LightCycler Real-Time PCR and Fluorescence Resonance Energy Transfer Hybridization Probe Melting Curve Analysis , 2002, Journal of Clinical Microbiology.

[2]  W. Keitel,et al.  Characterization of Bactericidal Immune Responses following Vaccination with Acellular Pertussis Vaccines in Adults , 2000, Infection and Immunity.

[3]  George Georgiou,et al.  Isolation and expression of recombinant antibody fragments to the biological warfare pathogen Brucella melitensis. , 2003, Journal of immunological methods.

[4]  W J Harris,et al.  Escherichia coli skp chaperone coexpression improves solubility and phage display of single-chain antibody fragments. , 1999, Protein expression and purification.

[5]  J. Hedrick,et al.  Acellular Pertussis Vaccine Booster Combined With Diphtheria and Tetanus Toxoids for Adolescents , 2006, Pediatrics.

[6]  R. Poljak,et al.  Structure and Thermodynamics of Antigen Recognition by Antibodies a , 1995, Annals of the New York Academy of Sciences.

[7]  S. Jadhav,et al.  Composition of acellular pertussis and combination vaccines: a general review. , 1999, Biologicals : journal of the International Association of Biological Standardization.

[8]  K. J. Kim,et al.  Monoclonal antibodies to pertussis toxin: utilization as probes of toxin function. , 1989, Hybridoma.

[9]  A. Plückthun,et al.  Reliable cloning of functional antibody variable domains from hybridomas and spleen cell repertoires employing a reengineered phage display system. , 1997, Journal of immunological methods.

[10]  David Baker,et al.  Recapitulation and design of protein binding peptide structures and sequences. , 2006, Journal of molecular biology.

[11]  W. N. Burnette,et al.  Epitopes on the S1 subunit of pertussis toxin recognized by monoclonal antibodies , 1989, Infection and immunity.

[12]  J. Kerr.  Pathogenesis of human parvovirus B19 in rheumatic disease , 2000, Annals of the rheumatic diseases.

[13]  Y. Arakawa,et al.  DNA vaccine encoding pertussis toxin S1 subunit induces protection against Bordetella pertussis in mice. , 2003, Vaccine.

[14]  J. Cherry,et al.  Detection of antibodies inhibiting the ADP-ribosyltransferase activity of pertussis toxin in human serum , 1992, Journal of clinical microbiology.

[15]  J. Barbieri,et al.  Assignment of functional domains involved in ADP-ribosylation and B-oligomer binding within the carboxyl terminus of the S1 subunit of pertussis toxin , 1994, Infection and Immunity.

[16]  Pertussis toxin S1 mutant with reduced enzyme activity and a conserved protective epitope. , 1988 .

[17]  G. Siber,et al.  Protective Effects of Pertussis Immunoglobulin (P-IGIV) in the Aerosol Challenge Model , 1999, Clinical Diagnostic Laboratory Immunology.

[18]  E. Hewlett,et al.  Tn5-induced mutations affecting virulence factors of Bordetella pertussis , 1983, Infection and immunity.

[19]  W. N. Burnette,et al.  Pertussis toxin S1 mutant with reduced enzyme activity and a conserved protective epitope. , 1988, Science.

[20]  J. Gornbein,et al.  A search for serologic correlates of immunity to Bordetella pertussis cough illnesses. , 1998, Vaccine.

[21]  F. Mooi,et al.  Crucial role of antibodies to pertactin in Bordetella pertussis immunity. , 2003, The Journal of infectious diseases.

[22]  A. Folgori,et al.  Mimicking of discontinuous epitopes by phage-displayed peptides, II. Selection of clones recognized by a protective monoclonal antibody against the Bordetella pertussis toxin from phage peptide libraries. , 1993, Gene.

[23]  G. Siber,et al.  Quantitative Priming with Inactivated Pertussis Toxoid Vaccine in the Aerosol Challenge Model , 2002, Infection and Immunity.

[24]  K. Mills.  Immunity to Bordetella pertussis. , 2001, Microbes and infection.

[25]  M. Schmidt,et al.  Elucidation of linear epitopes of pertussis toxin using overlapping synthetic decapeptides: identification of a human B-cell determinant in the S1 subunit indicative of acute infections. , 1994, Microbial pathogenesis.

[26]  H. Sato,et al.  Effect of monoclonal antibody to pertussis toxin on toxin activity , 1987, Infection and immunity.

[27]  T. B. Waggener,et al.  IS PERTUSSIS IMMUNE GLOBULIN EFFICACIOUS FOR THE TREATMENT OF HOSPITALIZED INFANTS WITH PERTUSSIS?: NO ANSWER YET , 2007, The Pediatric infectious disease journal.

[28]  David E. Kim,et al.  Computational Alanine Scanning of Protein-Protein Interfaces , 2004, Science's STKE.

[29]  R. Rappuoli,et al.  Mapping of a Protective Epitope of Pertussis Toxin by In Vitro Refolding of Recombinant Fragments , 1988, Bio/Technology.

[30]  F. Mooi,et al.  Adaptation of Bordetella pertussis to vaccination: a cause for its reemergence? , 2001, Emerging infectious diseases.

[31]  Zhiping Weng,et al.  Docking unbound proteins using shape complementarity, desolvation, and electrostatics , 2002, Proteins.

[32]  E. Hewlett,et al.  Induction of a novel morphological response in Chinese hamster ovary cells by pertussis toxin , 1983, Infection and immunity.

[33]  D. Burns,et al.  Use of Pertussis Toxin Encoded by ptxGenes from Bordetella bronchiseptica To Model the Effects of Antigenic Drift of Pertussis Toxin on Antibody Neutralization , 2000, Infection and Immunity.

[34]  H. Sato,et al.  Comparison of pertussis toxin (PT)-neutralizing activities and mouse-protective activities of anti-PT mouse monoclonal antibodies , 1991, Infection and immunity.

[35]  T. Murphy,et al.  Historical comparisons of morbidity and mortality for vaccine-preventable diseases in the United States. , 2007, JAMA.

[36]  R. Read,et al.  Crystal structure of the pertussis toxin-ATP complex: a molecular sensor. , 1996, Journal of molecular biology.

[37]  W. N. Burnette,et al.  Identification of a region in the S1 subunit of pertussis toxin that is required for enzymatic activity and that contributes to the formation of a neutralizing antigenic determinant. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[38]  A R Rees,et al.  WAM: an improved algorithm for modelling antibodies on the WEB. , 2000, Protein engineering.

[39]  R. Read,et al.  The crystal structure of pertussis toxin. , 1994, Structure.

[40]  Sergey Lyskov,et al.  The RosettaDock server for local protein–protein docking , 2008, Nucleic Acids Res..

[41]  D. Galas,et al.  A simple method for site-directed mutagenesis using the polymerase chain reaction. , 1989, Nucleic acids research.

[42]  H. Hallander,et al.  Levels of anti-pertussis antibodies related to protection after household exposure to Bordetella pertussis. , 1998, Vaccine.

[43]  L. Nencioni,et al.  Mutants of pertussis toxin suitable for vaccine development. , 1989, Science.

[44]  D. Baker,et al.  A simple physical model for binding energy hot spots in protein–protein complexes , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[45]  R. Schneerson,et al.  Correlation between pertussis toxin IgG antibodies in postvaccination sera and subsequent protection against pertussis. , 2000, The Journal of infectious diseases.

[46]  G. Cohen,et al.  Interactions of protein antigens with antibodies. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[47]  George Georgiou,et al.  Protection against anthrax toxin by recombinant antibody fragments correlates with antigen affinity , 2002, Nature Biotechnology.

[48]  Nimrod D. Rubinstein,et al.  Epitope mapping using combinatorial phage-display libraries: a graph-based algorithm , 2006, Nucleic acids research.

[49]  David M. Kranz,et al.  Dissecting Cooperative and Additive Binding Energetics in the Affinity Maturation Pathway of a Protein-Protein Interface* , 2003, Journal of Biological Chemistry.

[50]  H. Sato,et al.  Protective activities in mice of monoclonal antibodies against pertussis toxin , 1990, Infection and immunity.

[51]  S. Subramaniam,et al.  Modeling the structure of the combining site of an antisweet taste ligand monoclonal antibody NC10.14. , 1998, Biopolymers.